Recovery Protocol Guide
BPC-157 + TB-500 Recovery Stack Protocol
The BPC-157 and TB-500 stack is the most-studied peptide combination in preclinical tissue-repair research. This guide summarizes published protocols — mechanism overlap, dosing ratios, loading vs. maintenance phases, route of administration, storage, and common endpoints — so you can design a defensible research plan.
For in-vitro and laboratory animal research use only. Not for human consumption. Follow your institution's IACUC-approved protocol.
Bottom line: The BPC-157 + TB-500 recovery stack pairs a local angiogenic peptide (BPC-157, 250–500 mcg daily SC) with a systemic actin-regulating peptide (TB-500, 2.0–2.5 mg 2–3× weekly SC during a 4-week loading phase, then weekly during a 4-week maintenance phase). The two peptides cover complementary arms of tissue repair, are not mixed in the same syringe, and remain stable refrigerated for ~30 days after reconstitution in bacteriostatic water.
Why the Stack Works: Mechanism Overlap
BPC-157 and TB-500 act on different but complementary pathways of tissue repair. BPC-157 (Body Protective Compound-157) is a 15-amino acid sequence isolated from gastric juice that upregulates VEGF expression, accelerates angiogenesis, and modulates the NO-system locally at the injury site. TB-500 (Thymosin Beta-4 4-amino acid fragment) is a 43-amino acid peptide that binds G-actin, regulates the actin cytoskeleton, and mobilizes endothelial and progenitor cells systemically.
In simple terms: BPC-157 builds the vascular and growth-factor infrastructure at the injury site, and TB-500 mobilizes the repair cells that travel into that infrastructure. Stacking them addresses both the local and systemic arms of repair, which is why most preclinical tendon, ligament, and muscle-recovery protocols use them together.
Reference Dosing Protocol
| Phase | BPC-157 | TB-500 | Duration |
|---|---|---|---|
| Loading | 250–500 mcg SC daily (often split AM/PM) | 2.0–2.5 mg SC 2–3× per week | Weeks 1–4 |
| Maintenance | 250 mcg SC daily | 2.0–2.5 mg SC once weekly | Weeks 5–8 |
| Washout | Discontinue | Discontinue | Weeks 9–12 |
Figures are reference points compiled from published preclinical literature, not dosing instructions. Adjust per your IACUC-approved protocol.
Route of Administration
- Subcutaneous (preferred): reproducible absorption, minimal tissue trauma, used in the majority of published protocols.
- Intramuscular / peri-lesional: sometimes used for BPC-157 in tendon and ligament models when localization to the injury site is desired.
- Do not co-mix: reconstitute BPC-157 and TB-500 in separate vials with bacteriostatic water and administer in separate injections.
Reconstitution and Storage
Both peptides reconstitute cleanly in 0.9% benzyl alcohol bacteriostatic water. Typical reconstitution volumes: add 2 mL BAC water to a 5 mg BPC-157 vial (yields 2.5 mg/mL) and 2 mL BAC water to a 5 mg TB-500 vial (yields 2.5 mg/mL). Refer to the peptide calculator to convert mg/mL into injection units.
- Refrigerated (2–8 °C): stable for approximately 30 days after reconstitution.
- Frozen (−20 °C, single-use aliquots): stable for several months; thaw once and discard unused portion.
- Lyophilized vials: store at −20 °C; stable for 24+ months when sealed.
Common Research Endpoints
- Histological repair score (collagen organization, fiber alignment) at week 4 and week 8.
- Tensile strength testing of tendon or ligament tissue at terminal endpoint.
- Imaging (MRI / high-frequency ultrasound) for soft-tissue repair models.
- Biomarker panels: VEGF, FGF-2, IGF-1, and inflammatory markers (IL-6, TNF-α).
Related Guides
Frequently Asked Questions
Why stack BPC-157 with TB-500 in recovery research?
The two peptides act on complementary pathways: BPC-157 drives angiogenesis and growth-factor signaling (VEGF, FGF, EGF) at the local injury site, while TB-500 (Thymosin Beta-4) regulates actin polymerization and mobilizes progenitor cells systemically. Together they cover both the vascular scaffolding and the cellular migration arms of tissue repair, which is why the stack is one of the most studied recovery protocols in animal models.
What dosing ratios are typically used in published protocols?
Most preclinical recovery protocols use BPC-157 at 250–500 mcg per subject per day (often split AM/PM) and TB-500 at 2.0–2.5 mg per subject 2–3 times per week during a 4-week loading phase, then 2.0–2.5 mg once weekly during a 4-week maintenance phase. Always follow your IACUC-approved protocol — these figures are reference points from the literature, not dosing instructions.
Subcutaneous or intramuscular for the stack?
Subcutaneous administration is the most common route in published research because it is reproducible and reduces tissue trauma. Some tendon and ligament protocols use intramuscular or peri-lesional injection of BPC-157 for proximity to the injury site. Reconstitute both peptides with bacteriostatic water; do not mix the two peptides in the same syringe.
How long is a typical recovery research cycle?
Published cycles run 4–8 weeks. A common structure is a 4-week intensive loading phase (BPC-157 daily, TB-500 2–3x/week) followed by a 4-week taper or maintenance phase (BPC-157 daily, TB-500 once weekly). Endpoints are typically histological repair scores, tensile strength testing, or imaging at week 4 and week 8.
Are there known interactions or contraindications in research models?
No clinically relevant interactions have been reported between BPC-157 and TB-500 in the published animal literature, and toxicity studies on each peptide individually have not surfaced dose-limiting toxicity in standard research dose ranges. Both peptides remain investigational and are sold strictly for in-vitro and laboratory animal research use only — not for human consumption.
How should the reconstituted peptides be stored during a protocol?
Reconstituted BPC-157 and TB-500 are stable refrigerated at 2–8 °C for approximately 30 days in bacteriostatic water. For longer protocols, aliquot into single-use vials and store at −20 °C; thaw once and discard unused portion. See our peptide storage guide for full stability data.
